Published research on Retatrutide: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of metabolic research.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 2 recruiting, 9 active not recruiting, 21 completed.
Number of PubMed records mentioning Retatrutide, 2016 to 2026 (2026 is year to date).
Most recently started of 33 ClinicalTrials.gov entries.
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 · Recruiting · Phase 2 · started 2026-02-15A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 · Active Not Recruiting · Phase 3 · started 2026-01-24A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · Active Not Recruiting · Phase 3 · started 2025-11-17A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Recruiting · Phase 3 · started 2025-10-15A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 · Completed · Phase 1 · started 2025-06-06A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 · Active Not Recruiting · Phase 1 · started 2025-06-02A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Active Not Recruiting · Phase 3 · started 2025-05-29A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · Active Not Recruiting · Phase 3 · started 2025-03-05To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 · Completed · Phase 1 · started 2025-02-03A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · Active Not Recruiting · Phase 3 · started 2024-11-01The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Active Not Recruiting · Phase 3 · started 2024-04-30Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · Completed · Phase 3 · started 2024-04-10Positive coverage and opinions: this section collects news and commentary that read favorably.
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialEli Lilly and Company (investor.lilly.com) · May 21, 2026Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsEli Lilly and Company (via PR Newswire) · Jun 6, 2026Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CEli Lilly and Company (via PR Newswire) · Jul 23, 2026Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesEli Lilly and Company (via PR Newswire) · Sep 29, 2026Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialEli Lilly and Company (investor.lilly.com) · Dec 11, 2025Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA applicationReuters · Jul 23, 2026Eli Lilly to offer early access to next-gen obesity drug to some patientsReuters · Aug 3, 2026Lilly sets up next-gen obesity war with phase 3 retatrutide dataFierce Biotech · Sep 30, 2026Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.The Lancet · Published Sep 29, 2026 (issue Oct 10) · PubMedRetatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.New England Journal of Medicine · Sep 29, 2026 · PubMedGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutrition in Clinical Practice · 2026 Oct issue · PubMedFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug AdministrationFDA Intends to Take Action Against Non-FDA-Approved GLP-1 DrugsU.S. Food and Drug Administration · Feb 6, 2026Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.Rapid Commun Mass Spectrom · 2026 Dec 15 · Carneiro GRA et al. · PubMedRetatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes Obes Metab · 2026 Aug 17 · Ruotolo G et al. · PubMedDevelopment and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.J Chromatogr A · 2026 Jul 21 · Tong LH et al. · PubMedEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes Obes Metab · 2026 Sep 29 · Amjad MM et al. · PubMedObstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.Clin Oral Investig · 2026 Sep 14 · Comisi JC · PubMedAdvances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.Front Endocrinol (Lausanne) · 2026 Sep 7 · Mehetre KN et al. · PubMedRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes Metab Syndr Obes · 2026 Sep 2 · Puspitasari IM et al. · PubMedPharmacological management of obesity: Current landscape and emerging therapies.Indian J Pharmacol · 2026 Sep 2 · Atal S et al. · PubMedEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med · 2026 Sep 1 · Moiz A et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.